IP Library Granted Patent US 12,338,494
Granted Patent B2
US 12,338,494 · App. 18/321,141 · Granted Jun 24, 2025

Reagent and method for fluorescence quantitative real-time PCR detection of RCL

Inventors: Fang Liu (Shanghai, CN); Liping Lan (Shanghai, CN); Yutian Wei (Shanghai, CN); Xun Ye (Shanghai, CN); Li Zhang (Shanghai, CN); Jiaqi Huang (Rockville, MD); Yihong Yao (Rockville, MD)
Assignee: ABELZETA INC.
C12Q1/6876C12Q1/686C12Q1/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,494
App. No.
18/321,141
Granted
Jun 24, 2025
Kind
B2
Abstract

The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

Claims (14)

1. A reagent combination comprising:

(i) a first primer pair for specific amplification of vesicular stomatitis virus G protein (VSV-G) gene and a first probe, wherein, the first primer pair comprises: a first forward primer consisting of the sequence of SEQ ID NO: 1, and a first reverse primer consisting of the sequence of SEQ ID NO: 2;

wherein the first probe consists of the sequence of SEQ ID NO: 3 and a first detectable label; or

(ii) a second primer pair for specific amplification of VSV-G gene and a second probe, wherein, the second primer pair comprises: a second forward primer consisting of the sequence of SEQ ID NO: 4, and a second reverse primer consisting of the sequence of SEQ ID NO: 5;

wherein the second probe consists of the sequence of SEQ ID NO: 6 and a second detectable label; and further comprises

a third primer pair for specific amplification of a reference gene and a third probe,

wherein, the third primer pair comprises: a third forward primer consisting of the sequence of SEQ ID NO: 25, and a third reverse primer consisting of the sequence of SEQ ID NO: 26;

and, the third probe consists of the sequence of SEQ ID NO: 27 and a third detectable label.

2. The reagent combination of claim 1 , wherein the amplification efficiency of the reagent combination for detecting replication competent lentivirus (RCL) is ≥90%.

3. A detection kit comprising the reagent combination of claim 1 .

4. The detection kit of claim 3 , wherein the kit further comprises reagents for amplification.

5. The reagent combination of claim 2 , wherein the amplification efficiency of the reagent combination for detecting replication competent lentivirus (RCL) is ≥92%.

6. The reagent combination of claim 2 , wherein the amplification efficiency of the reagent combination for detecting replication competent lentivirus (RCL) is ≥95%.

7. The reagent combination of claim 1 , wherein the first, second and third detectable labels are fluorophores.

Assignments (5)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2023
From: LIU, FANG; LAN, LIPING; WEI, YUTIAN; YE, XUN; ZHANG, LI; HUANG, JIAQI; YAO, YIHONG
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 063714/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2023
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 063714/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2023
From: WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 063715/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2023
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP, INC.
Reel/Frame 063715/0281 →
Priority Claims (1)
CN 201810114113.2 · Feb 5, 2018 · national
Continuity (2)
Continuation 16967659
Related Publication 20230287495A1 · Sep 14, 2023
References Cited (4)
US 20040208849A1 · Bell · 2004 [cited by examiner]
US 20110070586A1 · Slezak · 2011 [cited by examiner]
US 20150376612A1 · Lee · 2015 [cited by examiner]
Lowe, T. et al. A computer program for selection of oligonucleotide primers for polymerase chain reaction. Nucleic Acids Research, vol. 18, No. 7, p. 1757-1761, (1990). [cited by examiner]